Project description
Nanoparticle-based therapy for breast cancer
Triple negative breast cancer (TNBC) accounts for nearly 20 % of all breast cancer cases and is characterised by aggressiveness and poor survival. Since most therapies fail, the EU-funded HypoCyclo project is seeking innovative alternatives. Scientists propose to deliver an optimal combination of chemotherapy and photodynamic therapy (PDT) using nanoparticles. Alongside effective drugs such as paclitaxel, nanoparticles will carry photosensitisers and oxygen-releasing agents to counteract tumour hypoxia and improve treatment efficacy. The idea is to combine nanoparticle administration with lasers and fibre-optics that facilitate interstitial and intra-operative light delivery. Researchers are envisaging a simple nanoparticle synthesis protocol to ensure low-cost and hence large-scale production.
Objective
Among all breast cancers (BC) affecting female population worldwide, 20% is represented by Triple Negative Breast Cancer (TNBC), an aggressive subtype with very limited therapeutic options and poor survival. Seeking for innovative TNBC therapies, HypoCyclo aims at the optimal combination of chemotherapy and photodynamic therapy (PDT). We envisage novel, tailored cyclodextrin (CyD)-based polymeric nanoparticles (NPs) able to load “known” therapeutic agents and decorated with a photosensitizer as well as an Oxygen-Releasing Agent. HypoCyclo focuses on the very effective drug paclitaxel (PCX) presenting several treatment problems like water insolubility. Biocompatible, novel CyD polymers are expected to solubilize and encapsulate through non-covalent binding the drug of choice in order to implement PCX chemotherapy with PDT, through the decoration with a PS able to generate antitumor reactive oxygen species (ROS) in situ. Indeed, PDT has become a very challenging yet feasible option thanks to the technological advances in lasers and fiber-optics allowing interstitial and intra-operative light delivery for the treatment of solid tumours, including BC. Finally, as hypoxia in BC tissue compromises standard chemotherapy and PDT, we will tailor our NPs with an ORA able to release oxygen in cells, enabling an alternative ROS source. The PCX loaded NPs will be completely characterized and tested in 2D and 3D TNBC models. Our goal is to keep the synthetic protocols simple, low-cost and green to facilitate industrial upgrade of the loaded multimodal NPs endowed with improved in vitro efficacy. Two partners, the SME Cyclolab and UNIBO, both already collaborating with the supervisor, will give the necessary support in mixed-CyD polymer synthesis and in the biological assays, respectively, guaranteeing a successful outcome. The project foresees a demanding training program for ER that will help him to become an independent researcher with a complete profile.
Fields of science
Keywords
Programme(s)
Funding Scheme
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinator
00185 Roma
Italy